Calamos Advisors
EBS icon

Calamos Advisors’s Emergent Biosolutions EBS Stock Holding History

Calamos Advisors’s Portfolio EBS Stock Details EBS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-10,100
Closed -$367K – 620
2016
Q1 		$367K Buy
10,100
+4,200
+71% +$148K ﹤0.01% 573
2015
Q4 		$236K Sell
5,900
-5,900
-50% -$206K ﹤0.01% 622
2015
Q3 		$336K Buy
+11,800
New +$389K ﹤0.01% 625

Other funds holding EBS

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GT
Glenmede Trust Philadelphia, Pennsylvania $20.4B AUM
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Calamos Advisors's EBS Position: Q2 2016 in Review

Calamos Advisors sold out of Emergent Biosolutions (EBS) in Q2 2016, closing a stake of 10,100 shares — an estimated $367K sold.

Calamos Advisors first reported a position in EBS in Q3 2015 and held it in 3 quarters. The position peaked at $367K in Q1 2016. 224 funds tracked by Wall St. Rank hold EBS as of Q2 2016.

  • Calamos Advisors reported no remaining Emergent Biosolutions position as of Q2 2016 after selling out during the quarter.
  • Calamos Advisors sold 10,100 Emergent Biosolutions shares in Q2 2016, an estimated $367K.
  • Calamos Advisors first reported a position in Emergent Biosolutions in Q3 2015 and held it in 3 quarters.
  • Calamos Advisors's Emergent Biosolutions position peaked at $367K in Q1 2016.
  • 224 funds tracked by Wall St. Rank held Emergent Biosolutions as of Q2 2016.

Based on Calamos Advisors's 13F filing for Q2 2016, filed 26 Jul 2016.